Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Nuvalent Inc (NUVL) Price & Performance

iShares S&P GSCI Commodity-Indexed Trust ETFTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

iShares S&P GSCI Commodity-Indexed Trust ETF vs Nuvalent Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.88, while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.

GSGNUVL
Sector
Commodities - Metals/AgricultureTechnology
52-Week High
$34.77$123.96
52-Week Low
$22.06$72.16
Market Cap
$9.81B
Enterprise Value
$8.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares S&P GSCI Commodity-Indexed Trust ETF

GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $30.85, down 0.48% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though oscillators are neutral and short-term RSI signals suggest overbought conditions. Recent financial media highlights a thematic focus on commodities as a key market driver, with notable investors increasing exposure to the sector.

The outlook for GSG is tied to commodity price trends and broader economic developments. Investment opportunity lies in exposure to a constrained supply environment and inflation hedging. Primary risks include commodity price volatility, global economic slowdowns reducing demand, and the ETF's structure leading to tracking error or contango in futures markets.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.

The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares S&P GSCI Commodity-Indexed Trust ETF

GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.

Read more on GSG

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL